Revelation Biosciences, Inc. Share Price
Equities
REVB
US76135L5075
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.18 USD | +1.87% | -2.68% | -85.49% |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 3.56M 297M |
---|---|---|---|---|---|
Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | 9 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.68% |
1 day | +1.87% | ||
1 week | -2.68% | ||
Current month | -20.44% | ||
1 month | -16.15% | ||
3 months | -77.90% | ||
6 months | -87.67% | ||
Current year | -85.49% |
Managers | Title | Age | Since |
---|---|---|---|
James Rolke
CEO | Chief Executive Officer | 55 | 01/20/01 |
Chester Zygmont
DFI | Director of Finance/CFO | 44 | 01/20/01 |
Sandra Vedrick
IRC | Investor Relations Contact | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
George Tidmarsh
CHM | Chairman | 64 | 01/20/01 |
Jess Roper
BRD | Director/Board Member | 59 | 01/20/01 |
James Rolke
CEO | Chief Executive Officer | 55 | 01/20/01 |
Date | Price | Change | Volume |
---|---|---|---|
26/24/26 | 2.18 | +1.87% | 45,621 |
25/24/25 | 2.14 | +2.39% | 9,543 |
24/24/24 | 2.09 | +0.97% | 40,461 |
23/24/23 | 2.07 | +0.98% | 31,546 |
22/24/22 | 2.05 | -8.48% | 22,521 |
Delayed Quote Nasdaq, April 27, 2024 at 02:00 am IST
More quotesQuarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-85.49% | 3.56M | |
+1.51% | 42.75B | |
+8.57% | 41.34B | |
+49.22% | 41.61B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- REVB Stock